NEW TREATMENT Russian patent published in 2019 - IPC A61K31/519 A61K45/00 A61P43/00 A61P11/12 A61P1/00 A61P15/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to a means of activating or enhancing a cystic fibrous transmembrane conductance regulator (CFTR) in a patient. As such, it is proposed to use 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a salt thereof (versions), use thereof for producing a medicament for the same purpose and a corresponding method (versions). Disclosed are compositions of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one with a leukotriene receptor antagonist or CFTR potential (corrector) (versions) and a product for activating or enhancing CFTR (versions).

EFFECT: proposed 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one is effective in CFTR mutations and does not cause diarrhea; invention can be used in treating colitis, Crohn's disease, gluten's disease, irritable colon syndrome, disturbed absorption of bile acid or diverticulitis, cystic fibrosis, pancreatitis and Sjögren's syndrome.

28 cl, 19 dwg, 9 ex